GET DAILY SIGNALSCorcept Therapeutics (CORT) Reports +64% Revenue Surge in Q3 2026
Key Takeaways
- Third quarter 2026 revenue rose 64% year over year to $340.5 million, topping the consensus estimate of roughly $323.9 million.
- Adjusted earnings per share (EPS) came in at $1.01, beating analyst expectations of $0.79 by $0.22.
- The Korlym franchise and its authorized generic generated $249.1 million, while newly launched Lifyorli contributed $91.4 million in product revenue.
- Net income surged to $126.8 million, or $1.01 per diluted share, from $19.7 million, or $0.16 per share, a year earlier.
- Management reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, a move that left some investors underwhelmed.
- Cash and investments climbed to $662.3 million as of September 30, 2026.
Earnings Context and Why It Matters
Corcept Therapeutics has been navigating a pivotal commercial transition. Its endocrinology franchise, centered on Korlym for Cushing's syndrome, has shown steady growth, but the standout development in 2026 is Lifyorli (relacorilant), launched April 1 as a treatment for platinum-resistant ovarian cancer. This quarter gives investors an early, meaningful view of how quickly the oncology launch is scaling and whether the company can maintain momentum across both franchises. With a December decision date approaching for an expanded relacorilant indication, these results carry implications beyond a single quarter and help shape expectations for the company's multi-year growth path.
Reported Results
Corcept Therapeutics reported its third quarter 2026 results, for the period ended September 30, 2026, on November 3, 2026. Total product revenue reached $340.5 million, a 64% increase from $207.6 million in the same period of 2025 and above the analyst consensus of approximately $323.9 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adjusted EPS was $1.01, beating the consensus estimate of $0.79 by $0.22. On a generally accepted accounting principles (GAAP) basis, net income climbed to $126.8 million, or $1.01 per diluted share, compared with $19.7 million, or $0.16 per diluted share, in the prior-year quarter.
Revenue growth was driven by both franchises. Korlym and its authorized generic product generated $249.1 million, while Lifyorli contributed $91.4 million in its second full quarter on the market. Management reiterated full-year 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint slightly above the consensus of roughly $1.14 billion. Cash and investments totaled $662.3 million at quarter-end, up from $544.6 million three months earlier.
Market Reaction and Investor Sentiment
Despite the top- and bottom-line beats, CORT shares slipped about 3.9% in after-hours trading following the report. The primary driver was the company's decision to reiterate, rather than raise, its full-year revenue guidance. Investors had grown accustomed to upward revisions, particularly after the prior quarter's strong results and the rapid early uptake of Lifyorli. The reaffirmed range of $1.1 billion to $1.2 billion signaled confidence in the existing trajectory but fell short of the more aggressive outlook some shareholders were hoping for, underscoring how elevated expectations had become heading into the print.
Forward Outlook and Key Factors to Monitor
The most immediate catalyst for CORT is the FDA's decision on its resubmitted New Drug Application (NDA) for relacorilant in Cushing's syndrome, expected by December 17, 2026. An approval would broaden relacorilant's label and could meaningfully expand its addressable market in endocrinology.
On the oncology side, investors will track the continued ramp of Lifyorli, including patient growth and reimbursement dynamics. The company also reported positive results from its BELLA Part A Phase 2 trial in platinum-resistant ovarian cancer, with additional readouts across the broader relacorilant development program expected in the coming quarters.
Beyond oncology and endocrinology, data from the Phase 2b MONARCH study of miricorilant in MASH (metabolic dysfunction-associated steatohepatitis) and the planned Phase 3 trial of dazucorilant in ALS (amyotrophic lateral sclerosis) represent longer-horizon value drivers. Cost discipline, margin trends, and the pace of cash generation will also remain in focus as Corcept funds a broad clinical pipeline while commercializing two franchises.
Using AI Tools in My Research Process
From what I see, tools like Tickeron’s AI Screener help me quickly compare earnings-driven moves like this one against peers in the healthcare sector. I find it useful for spotting comparable setups without spending hours on manual screening, and it has become a regular part of how I evaluate quarterly results and sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CORT sees MACD Histogram crosses below signal line
CORT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 14, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 34 instances where the indicator turned negative. In 25 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CORT as a result. In 57 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
CORT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CORT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for CORT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in 283 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CORT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.323) is normal, around the industry mean (3.104). CORT's P/E Ratio (151.811) is considerably higher than the industry average of (-0.958). Projected Growth (PEG Ratio) (2.660) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (15.898) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drugs for the treatment of severe psychiatric and neurological diseases
Industry Biotechnology